SCIENCE INSPIRED BY NATURE. DRIVEN BY NATURE.
Innovating Venom-Derived
Therapeutics to
Transform Cancer Care
Celtic Biotech is a clinical-stage biopharmaceutical company
developing first-in-class peptide therapies from venom
proteins to treat cancer and improve patient outcomes.
Funded by the European Union
Life Science Review
TOP THERAPEUTICS COMPANY IN EUROPE
Our Lead Candidate
CB-24
A novel peptide therapy designed to target solid tumors and improve patient outcomes.
First-In-Class Therapeutics
Venom-derived peptides engineered for precision and potent anticancer activity.
Clinical Stage Development
Advancing CB-24 through clinical trials for solid tumors and pain management.
Our Pipeline
Building a future of better outcomes through innovative peptide therapeautics.
PROGRAM
INDICATION
PRECLINICAL
PHASE I
PHASE II
PHASE III
CB-24
CB-24
DISCOVERY
Non-Small Cell
Lung Cancer (NSCLC)
Pain Management
(Chronic Pain)
Undisclosed
Indications
- 55%
- 55%
- 15%
Completed
In Progress
€2.5M+
EU Grant Funding
Supporting our mission to advance innovative therapies.
CLINICAL
STAGE
Actively advancing CB-24 in clinical trials
20+
Years of Research
Decades of expertise in venom peptide science.
Global
Collaboration
Working with leading researchers and institutions worldwide.
Science. Innovation. Impact.
Our proprietary Peptide platform harnesses the power of nature to create targeted therapies with the potential to transform cancer care.
Targeted Precision
Designed to attack cancer, not healthy cells.